Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions Sep 28, 2022 07:12AM
Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease Aug 22, 2022 07:12AM
Resverlogix Announces Appointment of New Chief Scientific Officer Aug 15, 2022 06:00PM
Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders Jun 21, 2022 11:30PM
Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors Jun 8, 2022 07:12AM
View Older Stories

May 9, 2022 07:15AM Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study
Apr 19, 2022 05:05PM Resverlogix Announces One-Year Extension of Debenture
Mar 17, 2022 07:15AM Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine
Mar 9, 2022 01:39PM Resverlogix Corp. to Webcast Live at VirtualInvestorConferences.com March 10th
Feb 17, 2022 07:12AM Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada
Jan 18, 2022 07:15AM Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment
Dec 13, 2021 06:00AM Resverlogix Announces Corporate Update Webcast and Conference Call
Nov 3, 2021 08:00AM Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-African Economy to Support the Development of Apabetalone for COVID-19 Patients
Nov 1, 2021 08:30AM Resverlogix In Active Discussions With The Kingdom of Morocco’s Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Drug Apabetalone
Oct 29, 2021 08:30AM Resverlogix to Participate in Leading Scientific Conferences
Oct 13, 2021 08:00AM Resverlogix to Present at Upcoming Conferences
Oct 12, 2021 04:35PM Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial
Sep 13, 2021 08:00AM Study Demonstrates Resverlogix’s Apabetalone Treatment Significantly Improves Cognition and Reduces Cognitive Decline Among Patients with Both Cardiovascular Disease and Diabetes Mellitus
Sep 8, 2021 08:00AM Resverlogix Announces Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot Study
Jul 6, 2021 06:00AM Resverlogix Announces Management Change
Jun 23, 2021 12:16AM Resverlogix Announces Voting Results from the 2021 Meeting of Shareholders
Jun 3, 2021 08:04AM Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial Commercialization of Apabetalone for COVID-19 in the United States and Canada
May 5, 2021 10:01AM Resverlogix Announces US$6 Million Debenture Financing
Apr 27, 2021 01:41PM Resverlogix’s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease
Apr 20, 2021 08:00AM Apabetalone’s Positive Impact on COVID-19 in Human Lung Cells Published in Biomedicines
Apr 12, 2021 08:00AM Health Canada Issues Resverlogix Authorization to Begin Immediate Clinical Studies of Apabetalone for COVID-19
Mar 17, 2021 08:00AM Apabetalone’s Beneficial Effects on COVID-19 Published in Prestigious Scientific Journal Cell
Mar 15, 2021 10:34AM Apabetalone Treatment Prevents COVID-19 Infection of Human Lung Cells
Mar 12, 2021 04:30PM Resverlogix Announces Change in Fiscal Year-End to December 31
Mar 3, 2021 08:00AM New Published Evidence of Apabetalone’s Beneficial Effects on COVID-19
Jan 27, 2021 05:35PM Resverlogix Reschedules Update Webcast and Conference Call
Jan 18, 2021 07:30AM Resverlogix Announces Update Webcast and Conference Call
Jan 12, 2021 08:00AM Apabetalone’s Positive Effect on Hospitalized Patients Involving Heart Failure
Dec 22, 2020 05:17PM Resverlogix Announces Voting Results from the 2020 Meeting of Shareholders and Update on $13 Million Investment by Sheikh Abdulgader Aboud Baeshen
Dec 22, 2020 07:30AM Resverlogix Announces Apabetalone Treatment Prior to SARS-CoV-2 (COVID-19) Exposure Significantly Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
Nov 20, 2020 06:28PM Resverlogix Files Notice of Annual and Special Meeting of Shareholders
Nov 12, 2020 08:00AM Resverlogix Announces Publication in High-impact, Peer-reviewed Journal, Clinical Epigenetics
Nov 2, 2020 07:30AM Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
Oct 26, 2020 08:00AM A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms
Oct 15, 2020 08:00AM Resverlogix Announces Presentations at Leading Scientific Conferences
Oct 14, 2020 07:30AM Resverlogix Announces Conversion of US$12 Million Debenture Strengthening Balance Sheet
Oct 6, 2020 07:30AM Resverlogix Announces $13 Million Private Placement
Oct 2, 2020 06:14PM Resverlogix Confirms Interim Filings on SEDAR
Sep 25, 2020 06:30PM Resverlogix Provides Update Regarding Extension of its Filing Calendar
Sep 15, 2020 08:00AM Resverlogix Announces Publication in High-impact Peer-reviewed Journal – Medicinal Research Reviews
Sep 11, 2020 08:18PM Resverlogix Provides Update Regarding Extension of its Filing Calendar
Sep 8, 2020 08:00AM Resverlogix Announces Participation at the Upcoming Global Chinese Financial Forum (“GCFF”) Virtual Conference 2020 – Investing in Innovation
Aug 28, 2020 06:30PM Resverlogix Provides Update Regarding Extension of its Filing Calendar
Aug 14, 2020 06:19PM Resverlogix Announces Private Placement
Aug 4, 2020 08:00AM Resverlogix Announces Publication on Apabetalone in Cardiovascular Therapeutics
Jul 28, 2020 06:00PM Resverlogix Announces Extension of its Filing Calendar Based on Continuous Disclosure Exemption
Jul 22, 2020 07:00AM Resverlogix Secures One-Year Extension of Maturity Date of Debenture
Jun 22, 2020 07:00AM Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
Jun 9, 2020 08:30AM Resverlogix Announces Key BETonMACE Renal Data from Plenary Session Presentation at ERA-EDTA Virtual Congress
Jun 5, 2020 06:54PM Resverlogix Announces Corporate Update Conference Call & Webcast on June 10, 2020 and Upcoming Presentation at the 57th ERA-EDTA Virtual Congress on June 9, 2020
View Older Stories